Aurora Cannabis (NASDAQ:ACB) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Aurora Cannabis from “sell” to “hold.” Other firms have issued mixed views, but MarketBeat reports a consensus “Moderate Buy” rating.
• Aurora Cannabis reported quarterly EPS of $0.04, beating the consensus estimate of a $0.13 loss, while revenue of $47.62 million was slightly above expectations. The company remains unprofitable, with a negative net margin of 32.26%.
• The stock opened at $3.74, with a market capitalization of approximately $242.5 million and a 52-week range of $2.56 to $6.66. Institutional investors own about 47.63% of the company.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other research firms have also recently commented on ACB. BMO Capital Markets upgraded Aurora Cannabis to a "hold" rating in a research note on Wednesday, August 5th. Weiss Ratings raised Aurora Cannabis from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 26th. Finally, Zacks Research upgraded Aurora Cannabis from a "hold" rating to a "strong-buy" rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Aurora Cannabis presently has a consensus rating of "Moderate Buy".

Aurora Cannabis Stock Up 0.3%

NASDAQ:ACB opened at $3.74 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.80 and a current ratio of 5.36. The stock has a market capitalization of $242.50 million, a P/E ratio of -2.65 and a beta of 0.63. The company's 50-day simple moving average is $3.28 and its 200-day simple moving average is $3.34. Aurora Cannabis has a fifty-two week low of $2.56 and a fifty-two week high of $6.66.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.17. The firm had revenue of $47.62 million for the quarter, compared to analyst estimates of $47.45 million. Aurora Cannabis had a negative net margin of 32.26% and a positive return on equity of 4.37%. On average, equities analysts anticipate that Aurora Cannabis will post -0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aurora Cannabis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp grew its stake in shares of Aurora Cannabis by 9,615.6% in the first quarter. Jones Financial Companies Lllp now owns 52,270 shares of the company's stock worth $229,000 after acquiring an additional 51,732 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Aurora Cannabis by 4.1% in the first quarter. Goldman Sachs Group Inc. now owns 743,903 shares of the company's stock valued at $3,266,000 after acquiring an additional 29,099 shares in the last quarter. Engineers Gate Manager LP purchased a new position in Aurora Cannabis in the second quarter valued at $68,000. Tidal Investments LLC boosted its holdings in Aurora Cannabis by 6.0% in the second quarter. Tidal Investments LLC now owns 1,509,483 shares of the company's stock valued at $6,400,000 after purchasing an additional 86,045 shares during the period. Finally, Headlands Technologies LLC acquired a new position in Aurora Cannabis during the 2nd quarter worth $66,000. Hedge funds and other institutional investors own 47.63% of the company's stock.

Aurora Cannabis Company Profile

Aurora Cannabis Inc NASDAQ: ACB is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada's regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country's largest growers by cultivation capacity and production output.

The company's core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.